Wave Life Sciences' New Data From AATD Study Met Expectations, Wedbush Says

MT Newswires Live05-19

Wave Life Sciences' (WVE) new data from its RestorAATion-2 study of WVE-006 for Alpha-1 antitrypsin deficiency, or AATD, was in line with expectations and supports its competitive profile, Wedbush said in a Tuesday note.

The firm said the new data, from the 400-milligram multidose group and 600-milligram single-dose group, continues to demonstrate good consistency.

Wedbush said the company provided additional evidence that supports the restoration of the endogenous regulation of AAT protein production by WVE-006, including two additional cases of an acute phase response.

The firm said that feedback from the US Food and Drug Administration in mid-2026 could provide the company with an accelerated approval pathway.

The firm has an outperform rating on the stock and a $15 price target.

Price: 6.58, Change: +0.18, Percent Change: +2.81

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636857296?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 22:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636857296","market":"nz","top_or_hot":-1,"title":"Wave Life Sciences' New Data From AATD Study Met Expectations, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences' (WVE) new data from its RestorAATion-2 study of WVE-006 for Alpha-1 antitrypsin deficiency, or AATD, was in line with expectations and supports its competitive profile, Wedbush said in a Tuesday note.</p><p>The firm said the new data, from the 400-milligram multidose group and 600-milligram single-dose group, continues to demonstrate good consistency.</p><p>Wedbush said the company provided additional evidence that supports the restoration of the endogenous regulation of AAT protein production by WVE-006, including two additional cases of an acute phase response.</p><p>The firm said that feedback from the US Food and Drug Administration in mid-2026 could provide the company with an accelerated approval pathway.</p><p>The firm has an outperform rating on the stock and a $15 price target.</p><p>Price: 6.58, Change: +0.18, Percent Change: +2.81</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wave Life Sciences' New Data From AATD Study Met Expectations, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWave Life Sciences' New Data From AATD Study Met Expectations, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-19 22:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences' (WVE) new data from its RestorAATion-2 study of WVE-006 for Alpha-1 antitrypsin deficiency, or AATD, was in line with expectations and supports its competitive profile, Wedbush said in a Tuesday note.</p><p>The firm said the new data, from the 400-milligram multidose group and 600-milligram single-dose group, continues to demonstrate good consistency.</p><p>Wedbush said the company provided additional evidence that supports the restoration of the endogenous regulation of AAT protein production by WVE-006, including two additional cases of an acute phase response.</p><p>The firm said that feedback from the US Food and Drug Administration in mid-2026 could provide the company with an accelerated approval pathway.</p><p>The firm has an outperform rating on the stock and a $15 price target.</p><p>Price: 6.58, Change: +0.18, Percent Change: +2.81</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636857296","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636857296","pubTimestamp":1779202445,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Wave Life Sciences' (WVE) new data from its RestorAATion-2 study of WVE-006 for Alpha-1 antitrypsin deficiency, or AATD, was in line with expectations and supports its competitive profile, Wedbush sai","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","WVE":"Wave Life Sciences Pte. Ltd"},"translate_title":"Wedbush表示，Wave Life Sciences来自AATD研究的新数据符合预期","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WVE":1},"content_text":"Wave Life Sciences' (WVE) new data from its RestorAATion-2 study of WVE-006 for Alpha-1 antitrypsin deficiency, or AATD, was in line with expectations and supports its competitive profile, Wedbush said in a Tuesday note.The firm said the new data, from the 400-milligram multidose group and 600-milligram single-dose group, continues to demonstrate good consistency.Wedbush said the company provided additional evidence that supports the restoration of the endogenous regulation of AAT protein production by WVE-006, including two additional cases of an acute phase response.The firm said that feedback from the US Food and Drug Administration in mid-2026 could provide the company with an accelerated approval pathway.The firm has an outperform rating on the stock and a $15 price target.Price: 6.58, Change: +0.18, Percent Change: +2.81","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636857296","isCrawlerRequest":true}